NetworkNewsBreaks – Capricor Therapeutics, Inc. (NASDAQ: CAPR) Shares Surge on Details of Recent Meeting with FDA Regarding Intravenous CAP-1002
Capricor Therapeutics (NASDAQ: CAPR) shares are up 30% after the company said the U.S. FDA has indicated it is willing to accept the company’s proposal to use the Performance of the Upper Limb as the basis for the primary efficacy endpoint for clinical studies of CAP-1002 for the treatment of muscular dystrophy. Official minutes from the company's recent meeting with the regulatory agency also show support for submission of an Investigational New Drug (IND) application to clinically evaluate repeat intravenous administration of CAP-1002. "The FDA's response to our proposed clinical development plan supports our near-term objective of submitting an IND…







